ContraVir Pharmaceuticals (NASDAQ:CTRV)‘s stock had its “hold” rating reissued by Maxim Group in a report released on Thursday.
The analysts wrote, “Contravir announced that IND for CRV-431 (cyclophilin inhibitor) has been approved to move into the clinic for hepatitis B virus (HBV). Important to note is the design of the study, which in our view could potentially accelerate timelines for the HBV combination; TXL + CRV-431.””
Separately, ValuEngine raised ContraVir Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, May 2nd.
NASDAQ:CTRV traded up $0.14 during mid-day trading on Thursday, reaching $1.59. The company’s stock had a trading volume of 1,792 shares, compared to its average volume of 136,986. ContraVir Pharmaceuticals has a twelve month low of $1.30 and a twelve month high of $6.60.
An institutional investor recently raised its position in ContraVir Pharmaceuticals stock. Barclays PLC boosted its holdings in ContraVir Pharmaceuticals (NASDAQ:CTRV) by 81.7% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 534,032 shares of the biopharmaceutical company’s stock after buying an additional 240,052 shares during the period. Barclays PLC owned 0.63% of ContraVir Pharmaceuticals worth $125,000 at the end of the most recent reporting period.
ContraVir Pharmaceuticals Company Profile
ContraVir Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of antiviral drugs with a primary emphasis on the treatment of Hepatitis B virus (HBV) infections. It engages in the development of TXL, a lipid acyclic nucleoside phosphonate that delivers high intracellular concentrations of the active antiviral agent tenofovir diphosphate for the treatment of Hepatitis B; and CRV431, a novel drug candidate for the treatment of chronic HBV infection.
Receive News & Ratings for ContraVir Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraVir Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.